恩瑞格注意事项有哪些呢？

The usage and dosage of dispersible tablets are recommended for patients with iron accumulation, such as those who require long-term blood transfusions (blood transfusions up to 100 ml/kg) and whose serum ferritin exceeds 1000 micrograms/liter. According to the body weight, it is initially recommended to take a daily dose of 20 mg/kg of Enrig. Depending on the serum ferritin index, patients may need to adjust or increase the dose of Enrig. Generally, 5 mg/kg or 10 mg/kg will be taken. The dose is adjusted in units of kilograms, but the total dose should not exceed 30 mg/kg per day. Today let’s take a look at what are the precautions for Enrig?

Precautions for taking Enriga: Enriga may cause rash. Generally, the rash will disappear automatically without the need to adjust the dose or stop the medication; if the situation is serious or persistent, the medication should be stopped. The patient's vision or hearing may be affected. It should be taken 30 minutes before meals. It should be taken at the same time every day. It is not advisable to take Enrige with drugs containing aluminum (such as gastric acid neutralizers).

Common adverse reactions of taking Enrige: diarrhea, vomiting, headache, abdominal pain, fever, rash, increased serum creatinine, etc. Other adverse reactions: increased liver enzymes, cough, throat inflammation, urticaria. While taking medicine, patients with thalassemia are often physically weak, so they should live cautiously in daily life, adapt to cold temperatures, and pay attention to preventing external infections; engage in more outdoor activities; breathe fresh air; and perform appropriate physical exercises, Qigong exercises, Tai Chi, etc. to enhance physical fitness and disease resistance.

Enrig's chemical name is 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid. It is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron-removing agent approved by the US FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a 6 As a first-line drug for patients with thalassemia and iron overload over the age of 18, Enrego is highly selective for iron (Fe3+). It is a ligand with 3 protrusions that binds iron with high affinity in a 2:1 ratio.

The above is the content of the precautions, I hope it can help you!